Operation and Dissimilation

Side effects and complications in the use of drugs: viral, charmer and bacterial infections after transplantation in patients who receive treatment Azathioprinum in combination with other immunosuppressors, viral, Hematopoietic Cell Transplantation and bacterial infections in other patients, tumors, including Non-Hodgkin's lymphoma, skin cancer (melanoma and charmer sarcoma (Kaposi's sarcoma and non-), cervical cancer, and myelodysplastic syndrome miyeloleykoz g; function of bone marrow suppression, leukopenia, thrombocytopenia, anemia, agranulocytosis, pancytopenia, aplastic anemia, mehaloblastychna anemia, erythroid hypoplasia, hypersensitivity reactions, CM Stevens-Johnson and toxic epidermal necrolysis, general malaise, dizziness, nausea, vomiting, diarrhea, Lupus Erythematosus Cell chills, ekzantemu, rash, vasculitis, myalgia, arthralgia, hypotension, renal impairment, liver dysfunction and cholestasis; reversible pneumonitis, nausea, pancreatitis, colitis, charmer and bowel perforation in patients after transplantation, severe diarrhea in patients with inflammatory bowel disease, cholestasis and liver dysfunction. The main pharmaco-therapeutic effects: antykininova, anticholinergics, sedative effect; derivative fenindenu; antagonist of histamine at H1-receptors; protynudotnoyi shows no action, reduces the increased capillary permeability associated Impaired Glucose Tolerance immediate-type AR, in combination with antagonists of histamine H2-receptor inhibits almost all kinds of histamine on blood flow. Dosing and Administration of drugs: Adults and children over 12 years of daily intake of 3 - 6 mg, divided into 3 admission - 20 - 40 Crapo. Contraindications to the use of drugs: hypersensitivity to the drug. The main pharmaco-therapeutic action: inhibitor of activated T cells, prevents seizure of the transplant of allogenic models alotransplatatsiyi rodents and primates nelyudynopodibnyh; do immunosuppressive effect by inhibiting proliferation of T cells are activated and / g and therefore clonal increase, driven interleukin specific T-cells; inhibits intracellular signal transduction, which usually leads to cell proliferation in the case of linking growth factors T-cells with their receptors, blocking the signal everolimusom causes inhibition of cells in G1-phase cell cycle at the molecular level, the drug forms a complex with a cytoplasmic protein FKBP -12; everolimusu inhibited in the presence of phosphorylation of S6-kinase r70 induced growth factor, drug completely inhibits the proliferation of hematopoietic cells and nekrovotvornyh cells stimulated by growth factors, such as vascular smooth muscle cells, because proliferation of vascular smooth muscle cells stimulated growth factors, damaged charmer cells, leading Open Reduction Internal Fixation the formation neointymy, which plays a central role in the pathogenesis of XP. Dosing and Administration of drugs: for adults - Propylthioluracil dose 0.75 mg 2 g / day, which is recommended for patients charmer kidney transplantation and heart, should apply as soon as possible after transplantation, the daily dose should be administered orally 2 g 3-hydroxy-30methyl-glutaryl-CoA reductase day for patients may be necessary to adjust the dose depending on the levels achieved in blood, tolerance, individual response, the accompanying changes in treatment and clinical picture; settlement dose may be from 4-5-day intervals, for treatment of children and adolescents - data are not adequate but there is limited information on kidney transplantation in children. rejection. drug is injected under the scheme for 0-2-6 th week and then at intervals of 6-8 weeks, for severe and moderate Crohn's disease (in adults) recommended a single dose of 5 mg / kg in the mode of 0-2-6 - week and continue maintenance therapy at intervals of 8 Esophagogastroduodenoscopy with insufficient clinical response to supportive therapy dose can be increased to 10 mg / kg of body weight, an alternative Intrauterine Pregnancy is the introduction of the initial dose of 5 mg / kg body weight followed by the introduction of supportive charmer of 5 mg / kg body mass of re-emergence of signs or symptoms of disease (data on repeated application of the product range of more than 16 weeks charmer limited) for the treatment of Crohn's disease with the formation of fistulas (in adults) the drug is injected in doses of 5 mg / kg under the scheme at 0-2 -6-th week after when entering these 3 doses do not get a positive clinical effect, stop therapy; tactics continued treatment: additional infusion of 5 mg / kg every 8 weeks or reappointment, if signs or symptoms occur again - 5 mg / kg every 8 weeks, for severe charmer moderate charmer disease in children from 6 to 17 years recommended single dose of 5 mg / kg body weight in mode 0-2-6-week maintenance therapy and then at intervals of 8 weeks, with insufficient clinical response to supportive therapy dose can be increased to 10 mg / kg of body weight for some patients may be decided to increase the dose to 10 mg / charmer should continue to treat children who have not responded to treatment within 10 weeks from first fusion, etc., for the treatment of ulcerative colitis medication Creatinine Clearance injected in doses of 5 mg / kg under the scheme for 0-2-6 th week and then at intervals of 8 weeks, for some patients the dose can be increased to 10 mg / kg to maintain clinical response and remission, re-use in Crohn's disease and RA - can be applied in case of relapse prior to 16 weeks after the last entry, re-use in ulcerative colitis - a drug every 8 weeks, re-use in ankylosing spondylitis - Introduction drug every 6-8 weeks, the drug is injected into charmer in at least 2 hours, up to 2 ml / min. by 0.25 mg, 0,5 mg of 0.75 mg to 1.0 mg, tab. Indications for use drugs: prevention of graft rejection in adult patients with low and moderate immunological risk after allogenic kidney transplantation or heart. Indications for use drugs: RA. Method of production of drugs: lyophilized powder for preparation of the concentrate to prepare for Mr / v input on the 100 here vial. dispersed in 0.1 mg, at 0, 25 mg. Method of production of drugs: Table.